What Prokaryotics does

Prokaryotics Inc. is a privately held, discovery-stage biopharmaceutical company founded in 2017 as a spinout from Merck & Co., Inc. by a team of former senior Merck scientists including the head of that company's Antimicrobial Early Discovery Unit. The company is headquartered at the Institute for Life Science Entrepreneurship at Kean University in Union, New Jersey, and operates with a small team (approximately 1–10 personnel) focused exclusively on the discovery and early preclinical development of novel anti-infective agents.

The company's scientific platform targets bacterial cell envelope biogenesis, with particular emphasis on the outer membrane assembly machinery that Gram-negative bacteria use to resist antibiotic entry, as well as Gram-positive targets and antifungal programs against drug-resistant Candida, Aspergillus, and rare molds. The pipeline comprises multiple non-clinical programs: a β-lactam potentiation program (Tarocin) targeting wall teichoic acid biosynthesis to restore efficacy against MRSA; Gram-negative programs targeting MsbA-mediated lipopolysaccharide transport and the BamA β-barrel assembly complex; an Acinetobacter baumannii combination product pairing a bacterial cell wall inhibitor with polymyxin permeabilizers; and antifungal series targeting GPI cell wall biosynthesis. Two composition-of-matter and use patents have issued from the USPTO covering Tarocin adjuvants, and worldwide development and commercialization rights for the foundational assets were in-licensed from Merck, with additional compounds licensed from Fundación MEDINA and Northern Antibiotics.

The business model is asset-light and partnership-driven rather than commercial. Prokaryotics generates inflows from non-dilutive NIH/NIAID grant funding (cumulative $10M+ across twelve SBIR, R01, R21, and STTR awards between 2018 and 2025) and from licensing-related milestone payments and royalties under pharmaceutical partner agreements, most notably the January 2026 exclusive global license with Basilea Pharmaceutica for the broad-spectrum antifungal program carrying up to $48.5 million in potential milestone payments plus tiered royalties. Customers are effectively other pharmaceutical companies rather than end prescribers, and go-to-market is structured around advancing programs through preclinical proof-of-concept and then out-licensing clinical and commercial responsibility. Pamela Demain serves as CEO and Holly Sutterlin as President; Terry Roemer is Founder and CSO.

Name

Prokaryotics

Legal name

Prokaryotics Inc.

Website

https://prokaryotics.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Prokaryotics is a private, discovery-stage biopharmaceutical company spun out of Merck in 2017, developing novel antibacterial and antifungal drug candidates that target bacterial cell envelope biogenesis to overcome multidrug-resistant infections, and monetizing its preclinical pipeline through pharmaceutical licensing partnerships and NIH grants.

Ownership category

akta.pro rank

Product category

Antibiotic Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Novel antibiotic discovery
• Antibacterial drug development
• Antifungal drug discovery
• Cell envelope targeting
• Biopharmaceutical research services

Headquarters

HQ city

Union

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Licensing and Milestone Payments: Prokaryotics generates revenue through licensing agreements with pharmaceutical partners, receiving upfront payments, development milestones, regulatory milestones, and commercial milestones. The Basilea partnership includes potential development, regulatory, and commercial milestone payments up to $48.5 million plus tiered royalties.
2. NIH Grant Funding: Non-dilutive funding through NIH SBIR/STTR grants supporting various antibiotic and antifungal research programs. Multiple grants awarded including R01, R21, and SBIR Phase I/II awards totaling over $10 million historically.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Prokaryotics is a discovery-stage biopharmaceutical company developing novel antibiotics and antifungals that target bacterial and fungal cell envelope biogenesis. The company licenses its preclinical drug programs to larger pharmaceutical partners (e.g., Basilea Pharmaceutica) for clinical development and commercialization, generating revenue through upfront payments, development/regulatory/commercial milestones, and tiered royalties. Its pipeline targets multidrug-resistant Gram-negative and Gram-positive bacteria (including MRSA, Acinetobacter baumannii) and drug-resistant fungal pathogens (Candida, Aspergillus, rare molds).

Product overview

Prokaryotics is a privately-held biopharmaceutical company focused on the discovery and development of novel anti-infective drugs targeting antibiotic-resistant bacteria and fungi. The company emerged from licensing agreements with Merck & Co., Inc. and operates as an authentic antibacterial discovery organization. The product portfolio consists of multiple research and preclinical-stage programs targeting cell envelope biogenesis in both Gram-negative and Gram-positive bacteria, as well as antifungal programs. Key programs include: the Tarocin beta-lactam potentiation program (Phase 2, targeting MRSA), Gram-negative antibiotic programs targeting MsbA/LPS, the Acinetobacter baumannii combination product, the BamA inhibitor program, and antifungal programs including a broad-spectrum antifungal being developed in collaboration with Basilea Pharmaceutica. Prokaryotics leverages deep knowledge of bacterial physiology, innovative screening strategies, and medicinal chemistry expertise to develop next-generation antibiotics and antifungals.

Differentiator

Problem solved

Functional benefit

Products and services

• Antibiotic Discovery Programs - Cell Envelope Biogenesis
• Tarocin Beta-Lactam Potentiation Program

Quantifiable outcome

• Targeting the global antibiotic resistance crisis projected to have health and economic impact rivaling global warming

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core, major, notable and minor.

• Basilea Pharmaceutica LtdcoreStrategic or Co-development Partner · 7 January 2026Collaboration to jointly develop a first-in-class broad-spectrum antifungal for severe invasive infections caused by Candida, Aspergillus, and rare molds. Prokaryotics received undisclosed upfront payment and near-term milestones; potential total milestone payments up to USD 48.5 million plus tiered royalties. Basilea assumes responsibility for clinical development and global commercialization under exclusive global license.
• Fundación MEDINAmajorStrategic or Co-development PartnerExclusive worldwide licensing agreement for new antibiotic compounds from the Spanish foundation Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucia.
• Hackensack Meridian Health - Center for Discovery and Innovation (CDI)majorStrategic or Co-development PartnerCollaboration with CDI led by Dr. David Perlin, a leading infectious disease expert working on novel antibiotics to overcome drug-resistant bacteria.
• AiCuris Anti-infective Cures AGnotableStrategic or Co-development PartnerSelected by AiCuris for its AiCubator initiative to support innovation in infectious disease. Prokaryotics' bacterial cell envelope-targeting antibiotic program was recognized as a novel and scientifically attractive resistance-breaking opportunity of high priority.
• Institute for Life Science Entrepreneurship (ILSE)majorStrategic or Co-development PartnerLocated at ILSE at Kean University, providing access to research infrastructure and collaborative ecosystem for life science startups.
• INEOS OxfordminorStrategic or Co-development PartnerAcademic partnership for antibiotic research collaboration.
• SSG2minorStrategic or Co-development PartnerStrategic research partnership.
• University of FloridaminorStrategic or Co-development PartnerAcademic collaboration for infectious disease research.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Amplyx Pharmaceuticals: Pre-clinical/clinical antifungal developer of fosmanogepix (acquired by Pfizer in 2021) — directly comparable to Prokaryotics' antifungal franchise in target (invasive fungal infections) and partnership-driven value creation.
• Scynexis: Clinical/commercial antifungal developer of ibrexafungerp (BREXAFEMME), which was originally designed by Prokaryotics' Director of Chemistry R. Wilkening at Merck — making Scynexis the closest direct comparable to Prokaryotics' antifungal programs in target class and strategic model.
• Cidara Therapeutics: Clinical-stage anti-infective company developing antifungal and antibacterial drug-Fc conjugates (e.g., rezafungin) — directly comparable to Prokaryotics as a small-cap anti-infective biotech pursuing novel mechanisms against drug-resistant pathogens.
• VenatoRx Pharmaceuticals: Private clinical-stage antibiotic developer with programs targeting ESBL-producing Gram-negative bacteria and other resistant pathogens — directly comparable in pre-commercial antibiotic discovery model and partnering-oriented GTM.
• Iterum Therapeutics: Clinical-stage anti-infective company developing oral sulopenem for multidrug-resistant Gram-negative infections — directly comparable as a small-cap pharma focused on antibiotic-resistant pathogens.
• BioVersys: Swiss privately-held clinical-stage antibacterial company developing small molecules to overcome drug resistance via potentiators and direct-acting antibiotics — closely comparable to Prokaryotics' potentiation (Tarocin) and novel mechanism approach.
• Acurx Pharmaceuticals: Clinical-stage antibiotic developer with a DNA polymerase IIIC inhibitor (ibezapolstat) targeting C. difficile and Gram-positive infections — comparable as a small-cap pre-revenue antibacterial biotech with partner-driven commercialization.
• Nosopharm: French privately-held early-stage antibiotic company discovering novel classes from microbial biodiversity — directly comparable to Prokaryotics as a small-cap antibacterial R&D platform pursuing new mechanisms against resistant bacteria.
• Melinta Therapeutics: Antibiotic developer (Baxdela, Orbactiv, Kimyrsa) that emerged from Chapter 11 and remains a small-cap broad-spectrum antibiotic company — directly comparable as a commercial/clinical-stage antibacterial company despite financial distress history.

Broad incumbents

• Merck & Co., Inc. Original licensor of Prokaryotics' foundational antibacterial programs and the global pharma from which the founding team spun out — comparable as a BROAD_INCUMBENT operating its own antibacterial discovery unit while serving as Prokaryotics' upstream IP partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/prokaryotics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prokaryotics